Unique Effects of Perimenstrual Estradiol or Progesterone Supplementation on Perimenstrual Suicidality

Phase 4 Completed 60 enrolled University of Illinois at Chicago National Institute of Mental Health (NIMH) · collab

RandomizedCrossoverDouble-blindBasic science

Summary

This within-person, crossover, 3-condition, placebo-controlled study compares the impact of three perimenstrual conditions on severity of suicidal symptoms in females with past-month suicidality but minimal risk of imminent suicide attempt. The three conditions are (1) perimenstrual withdrawal from estradiol only (during progesterone stabilization), (2) perimenstrual withdrawal from progesterone only (during estradiol stabilization), and (3) perimenstrual withdrawal from both estradiol and progesterone during placebo.

Timeline

Start: 2018-07-27
Primary completion: 2021-05-09
Completion: 2021-05-09

Outcome

Mixed primary results

registry Transdermal Estradiol + Placebo vs Placebos; p = .002; Slope -.25 (95% CI -.41 to -.08) NCT03498313 ↗

registry Oral Micronized Progesterone + Placebo vs Placebos; p = .46; Slope -.06 (95% CI -.22 to .10) NCT03498313 ↗

Publications

Law KC, O'Connell KL, Barone JC, Eisenlohr-Moul TA. Examining Suicidal Ideation and Capability Across the Menstrual Cycle. Suicide Life Threat Behav. 2026 Apr;56(2):e70084. doi: 10.1111/sltb.70084.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Estradiol	Other / unclassified	0.1 mg	Other
Subject	Progesterone	Other / unclassified	100 mg	—

Indications

No indication recorded.